KR20160109093A - Method of preparing combined extract powder of fermented scutellariae radix and gastrodiae rhizoma from compounding solution of micro-organism and natural enzyne - Google Patents
Method of preparing combined extract powder of fermented scutellariae radix and gastrodiae rhizoma from compounding solution of micro-organism and natural enzyne Download PDFInfo
- Publication number
- KR20160109093A KR20160109093A KR1020150032888A KR20150032888A KR20160109093A KR 20160109093 A KR20160109093 A KR 20160109093A KR 1020150032888 A KR1020150032888 A KR 1020150032888A KR 20150032888 A KR20150032888 A KR 20150032888A KR 20160109093 A KR20160109093 A KR 20160109093A
- Authority
- KR
- South Korea
- Prior art keywords
- fermented
- extract
- gold
- fermentation
- complex
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 53
- 239000000843 powder Substances 0.000 title claims abstract description 36
- 244000005700 microbiome Species 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 39
- 238000013329 compounding Methods 0.000 title 1
- 241000208340 Araliaceae Species 0.000 claims abstract description 23
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 22
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 22
- 235000008434 ginseng Nutrition 0.000 claims abstract description 22
- 102000004190 Enzymes Human genes 0.000 claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 12
- 230000032683 aging Effects 0.000 claims abstract description 11
- 241000207929 Scutellaria Species 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 238000001694 spray drying Methods 0.000 claims abstract description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 67
- 239000010931 gold Substances 0.000 claims description 60
- 229910052737 gold Inorganic materials 0.000 claims description 60
- 238000000855 fermentation Methods 0.000 claims description 57
- 230000004151 fermentation Effects 0.000 claims description 57
- 239000012141 concentrate Substances 0.000 claims description 24
- 210000004207 dermis Anatomy 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 241000382353 Pupa Species 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 210000004913 chyme Anatomy 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 150000004684 trihydrates Chemical class 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 9
- 239000002131 composite material Substances 0.000 abstract description 9
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 230000003405 preventing effect Effects 0.000 abstract description 4
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 3
- 241000219780 Pueraria Species 0.000 abstract description 2
- 241000305492 Gastrodia Species 0.000 abstract 3
- 208000019736 Cranial nerve disease Diseases 0.000 abstract 1
- 208000014826 cranial nerve neuropathy Diseases 0.000 abstract 1
- 230000009471 action Effects 0.000 description 27
- 239000004480 active ingredient Substances 0.000 description 21
- 235000008504 concentrate Nutrition 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 12
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 12
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 241000411851 herbal medicine Species 0.000 description 7
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 6
- 230000001754 anti-pyretic effect Effects 0.000 description 6
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 6
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 6
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 6
- 229940025878 hesperidin Drugs 0.000 description 6
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 6
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 5
- 229940015301 baicalein Drugs 0.000 description 5
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 5
- 229930193974 gastrodin Natural products 0.000 description 5
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229960003321 baicalin Drugs 0.000 description 4
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 239000004519 grease Substances 0.000 description 4
- 210000002241 neurite Anatomy 0.000 description 4
- CQRYARSYNCAZFO-UHFFFAOYSA-N o-hydroxybenzyl alcohol Natural products OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000003858 Chymases Human genes 0.000 description 3
- 108090000227 Chymases Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- -1 Flabanone Natural products 0.000 description 3
- 241000282577 Pan troglodytes Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000006993 memory improvement Effects 0.000 description 3
- 230000014511 neuron projection development Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 3
- 235000012141 vanillin Nutrition 0.000 description 3
- QBQNMIPDPJEZHR-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methoxymethyl]-2-[(4-hydroxyphenyl)methyl]phenol Chemical compound C1=CC(O)=CC=C1COCC1=CC=C(O)C(CC=2C=CC(O)=CC=2)=C1 QBQNMIPDPJEZHR-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 241000555678 Citrus unshiu Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 235000007240 daidzein Nutrition 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229930013032 isoflavonoid Natural products 0.000 description 2
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 2
- 235000012891 isoflavonoids Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- ZENOXNGFMSCLLL-UHFFFAOYSA-N vanillyl alcohol Chemical compound COC1=CC(CO)=CC=C1O ZENOXNGFMSCLLL-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- CDDWAYFUFNQLRZ-KJVHGCRFSA-N (3beta,21beta,22beta)-olean-12-ene-3,21,22,24-tetrol Chemical compound C([C@@]12C)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3CC(C)(C)[C@@H](O)[C@@H](O)[C@]3(C)CC[C@]21C CDDWAYFUFNQLRZ-KJVHGCRFSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- QXQFFGOMXYKNBA-UHFFFAOYSA-N Chikusetsusaponin V Natural products CC1(C)CCC2(CCC3C(=CCC4C3(C)CCC5C(C)(C)C(CCC45C)OC6OC(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O QXQFFGOMXYKNBA-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000172412 Physalis pruinosa Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 229930192484 Skullcapflavone Natural products 0.000 description 1
- CZRGNFVQUYWGKP-UHFFFAOYSA-N Skullcapflavone I Natural products COC=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1O CZRGNFVQUYWGKP-UHFFFAOYSA-N 0.000 description 1
- 229930187719 Soyasaponin Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BJBKXYIIWYIZCX-UHFFFAOYSA-N Trigraecum Natural products C1=C(O)C(OC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BJBKXYIIWYIZCX-UHFFFAOYSA-N 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- SZMVKWFJCYTPOI-UHFFFAOYSA-N baicaline Natural products N1CCC2=C3OCOC3=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 SZMVKWFJCYTPOI-UHFFFAOYSA-N 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000010234 biliary secretion Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- HCFPRFJJTHMING-UHFFFAOYSA-N ethane-1,2-diamine;hydron;chloride Chemical compound [Cl-].NCC[NH3+] HCFPRFJJTHMING-UHFFFAOYSA-N 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- RBRANZURTULKJD-UHFFFAOYSA-N ginsenoside Ro Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C)(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O RBRANZURTULKJD-UHFFFAOYSA-N 0.000 description 1
- KVMXBSSOCCPAOR-UHFFFAOYSA-N ginsenoside ra1 Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC(C(C1O)O)OCC1OC1OCC(O)C(O)C1O KVMXBSSOCCPAOR-UHFFFAOYSA-N 0.000 description 1
- YLOTVUIQEWTDME-UHFFFAOYSA-N ginsenoside-Ra1 Natural products CC(=CCCC(C)(OC1OC(COC2OCC(OC3OCC(O)C(O)C3O)C(O)C2O)C(O)C(O)C1O)C4CCC5(C)C4C(O)CC6C7(C)CCC(OC8C(O)C(O)C(CO)OC8OC9OC(CO)C(O)C(O)C9O)C(C)(C)C7CCC56C)C YLOTVUIQEWTDME-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002630 limonoids Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical class C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- CDDWAYFUFNQLRZ-UHFFFAOYSA-N soyasapogenol A Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)C(O)C(O)C3(C)CCC21C CDDWAYFUFNQLRZ-UHFFFAOYSA-N 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A23L1/0035—
-
- A23L1/3002—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A23Y2220/03—
-
- A23Y2240/75—
-
- C12R1/85—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/85—Saccharomyces
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 미생물 및 천연효소를 이용하여 황금을 발효시킨 후 숙성 및 건조과정을 거쳐 발효황금을 제조한 다음, 발효황금에 천마, 진피, 갈근 및 인삼 등을 배합하여 용매로 추출, 농축, 분무 건조하여 제조한 발효황금 천마복합 분말에 관한 것이다. The present invention relates to a process for producing fermented gold by fermentation of gold using microorganisms and natural enzymes, followed by aging and drying processes, and then fermented gold is mixed with chymase, dermis, gruel and ginseng and extracted with a solvent, The present invention also relates to a fermented golden chromatin composite powder.
황금(Scutellaria Radix)은 속썩은풀(Scutellaria baicalensis)의 주피를 벗긴 뿌리로써, 한국, 중국, 일본 등에 자생하고 녹색을 띈 선황색을 이루고 쓴맛을 나타낸다. 황금의 유효성분은 플라보노이드(Flavonoid)로써 바이칼린(Baicaline)을 가장 많이 함유하고 있으며, 그 외에 바이칼레인(Baicalein), 우고닌(Wogonine), 오록실린A(Oroxylin A), 플라바논(flabanone) 및 스쿨캅플라본(skullcapflavone)등을 함유하고 있다. Golden (Scutellaria radix) is a peeled root of Scutellaria baicalensis. It is native to Korea, China, Japan, and has greenish purple and bitter taste. The active ingredient of gold is Flavonoid which is the most abundant of Baicaline and Baicalein, Wogonine, Oroxylin A, Flabanone, Skullcapflavone, and the like.
황금의 약리작용은 주로 해열작용, 항염증작용, 이담작용, 죽상동맥경화 방지작용,혈압 강하작용, 진정작용, 간세포보호작용, 신경세포보호작용 및 항종양작용을 가지고있는 것으로 알려져 있으며 그 외에도 항알러지작용, 호흡기질환개선작용, 자가면역질환 예방작용, 당뇨개선작용 등이 알려져 있다. 한방에서는 주로 소염해열약으로 염증, 충혈, 발열을 수반하는 질병, 특히 습열성 황달, 두통, 염증성 결막염, 호흡기감염, 위염, 장염 등에 황금탕, 갈근황련황금탕등으로 처방되고 있다 The pharmacological action of gold is known to have mainly antipyretic action, antiinflammatory action, dandruff action, atherosclerosis prevention action, hypotensive action, sedation, hepatocyte protective action, nerve cell protective action and antitumor action. An allergic action, a respiratory disease improvement action, an autoimmune disease prevention action, and a diabetic improvement action. In the oriental medicine, it is prescribing as the anti-inflammatory drug mainly inflammation, hyperemia and fever accompanied diseases such as hypertrophic jaundice, headache, inflammatory conjunctivitis, respiratory infection, gastritis, enteritis,
황금의 활성성분으로는 주로 바이칼린, 바이칼레인 및 우고닌에 대한 연구가 활발히 진행되고 있으며, 그 중 바이칼린은 담즙의 분비를 촉진시키고, 캐모카인의 생리적 기능을 억제하여 항염증작용을 나타내며, 바이칼레인은 바이칼린에 비하여 훨씬 높은 항산화활성을 가짐으로써 해열작용과 함께 혈압강하작용, 죽상동맥경화 방지작용, 신경세포보호작용, 혈관신생억제작용 등 순환계 질환에 유효한 작용을 나타내고, 우고닌은 항염증작용과 함께 간세포보호작용, 신경세포보호작용 등을 나타내는 것으로 보고 되어있다. Among the active ingredients of gold, studies on baicalin, baicalein and wogonin have been actively carried out. Among them, baicalin promotes secretion of bile, inhibits the physiological function of camokine and exhibits anti-inflammatory activity , Baicalein has a much higher antioxidant activity than baicalin, which is effective for circulatory diseases such as blood pressure lowering action, atherosclerosis preventing action, neuronal cell protection action and angiogenesis inhibitory action as well as antipyretic action. Have been reported to exhibit anti-inflammatory action as well as hepatocyte protective action and neuronal protective action.
천마(GASTRODIAE RIZOMA)는 난초과 식물의 덩이줄기로써 광택이 있고 각질 모양을 나타내며 단맛과 비린 맛을 함께 가지고 있다. 천마의 유효성분은 페놀 유도체로써 가스트로딘(gastrodin) 4-히드록시벤질알코올(4-hydroxybenzylalcohol), 4-히드록시벤즈알데히드(4-hydroxybenzaldehyde), 바닐린(vanillin), 바닐릴알코올(vanillyl alcohol) 및 가스트롤(gastrol)등을 함유하고 있다. 또한 피토스테롤(phytosterol)유도체로써 베타시토스테롤(β-sitosterol), 다우코스테롤(daucosterol) 및 캄페스테롤(campesterol)등을 함유하고 있다. GASTRODIAE RIZOMA is an orchidaceous plant stem that has a glossy, keratinized shape and has both sweet and savory flavor. The active ingredient of the horse root is a phenol derivative such as gastrodin 4-hydroxybenzylalcohol, 4-hydroxybenzaldehyde, vanillin, vanillyl alcohol and gas Gastrol and the like. It also contains phytosterol derivatives such as β-sitosterol, daucosterol and campesterol.
천마의 약리작용으로는 진정작용, 진경작용, 진통작용, 뇌세포보호작용 외에 담즙분비 촉진자용, 항전간작용 및 평활근 긴장 완화작용 등이 알려져 있다. 한방에서는 주로 진정, 진경약으로 두통, 현기증, 히스테리증, 전간, 반신불수, 사지경련, 안면마비, 동통 및 류마티스 등에 침향천마탕, 단하백출천마탕 등으로 처방되고 있다. The pharmacological actions of Chunma are known to induce biliary secretion, hepatic interactions, and smooth muscle relaxation, as well as sedation, analgesic action, analgesic action, and brain cell protective action. In the oriental medicine, it is mainly prescribed as calming, oriental medicine, such as headache, dizziness, hysteria, fullness, hemiplegia, cramps, facial paralysis, pain and rheumatism.
천마의 활성성분으로는 주로 가스트로딘, 4-히드록시벤즈알데히드, 바닐린 등에 대한 연구가 활발히 진행되고 있으며, 그중 가스트로딘은 기억력장애를 회복시키고 개선하며 신경전달 물질인 가바(GABA)분해효소를 억제함으로써 신경전달작용을 촉진시키고, 4-히드록시벤즈알데히드 및 바닐린은 뇌신경세포에 세포사멸을 억제하며, 가바관련 신경전달 작용을 증강시키는 것으로 보고되어 있다. Studies on gastrodine, 4-hydroxybenzaldehyde, vanillin, and the like have been actively carried out as active ingredients of Ganoderma lucidum, among which gastrodine restores and improves memory disorder and suppresses the neurotransmitter GABA 4-hydroxybenzaldehyde and vanillin have been reported to inhibit apoptosis in neuronal cells and enhance neurotransmitter action associated with GABA.
진피(Aurantii Nobilis Pericarpium)는 귤나무(Citrus unshiu)의 성숙한 과피로써 특이한 냄새가 있고 맛은 쓰면서 약간 자극성이 있다. 진피의 유효성분은 플라보노이드(Flavonoid)로써 헤스페리딘(Hesperidin)을 가장 많이 함유하고 있으며, 그 외에 루틴(Rutin), 나린긴(Naringin), 네오헤스페리딘(Neohesperidin)등을 함유하고 있다. 또한 리모노이드(Limonoid), 알칼로이드(Alkaloid) 및 정유 등을 함유하고 있다. The dermis (Aurantii Nobilis Pericarpium) is a mature rind of citrus unshiu (Citrus unshiu) with a peculiar odor and a slightly irritating flavor. The active ingredient of the dermis is Flavonoid which contains the most Hesperidin and also contains Rutin, Naringin, Neohesperidin and so on. It also contains limonoids, alkaloids and essential oils.
진피의 약리작용은 주로 모세혈관 강하작용, 혈중지질저하작용, 항알러지작용, 항염증작용, 건위작용, 구풍작용 및 항종양작용 등이 알려져 있다. 한방에서는 주로 소화불량, 가래를 동반한 기침 등에 이진탕, 이공산 및 귤피죽여탕 등으로 처방되고 있다. The pharmacological action of the dermis is mainly known as capillary lowering action, blood lipid lowering action, antiallergic action, antiinflammatory action, dryness action, vaginal action and antitumor action. In one room, it is prescribe mainly as dyspepsia, cough accompanied with sputum, and the like.
진피의 활성성분으로는 헤스페리딘에 대한 연구가 활발히 진행되고 있는데, 모세혈관강하작용, 혈중지질저하작용, 항알러지작용 등의 연구결과가 보고되어 있다. Studies on hesperidin as an active ingredient of dermis have been actively conducted, and research results such as capillary-lowering action, blood lipid lowering action, and anti-allergic action have been reported.
갈근(Puerariae Radix)은 칡(Pueraria lobata)의 죽피를 제거한 뿌리로써 냄새가없고, 맛은 달다. 갈근의 유효성분은 이소플라보노이드(Isoflavonoid)로써 퓨에라린(Puerarin), 다이드제인(Daidzein), 다이드진(Daidzin) 및 제니스테인(Genistein)등을 함유하고 있고, 트리테르페노이드(Triterpenoid)로써 소이아사포닌(Soyasaponin), 소이아사포게놀A(Soyasapogenol A)등을 함유하고 있다. 갈근의 약리작용으로는 해열작용, 진경작용, 순환계에대한 작용, 혈당강하작용, 간세포보호작용, 알코올섭취 억제작용, 항혈전작용, 항알러지작용 등이 알려져 있다. 한방에서는 주로 소염, 해열, 진경제로써 감기, 발열, 동통 및 근육통에 갈근탕 및 개지가갈근탕 등으로 처방되고 있다. Puerariae Radix is a bamboo root of Pueraria lobata that is odorless and tastes sweet. The active ingredient of Pueraria is isoflavonoid which contains Puerarin, Daidzein, Daidzin and Genistein and is a triterpenoid. Soyasaponin, Soyasapogenol A and the like. The pharmacological actions of Puerariae are known to be antipyretic, antipyretic, circulatory, hypoglycemic, hepatoprotective, alcoholic, antithrombotic, and allergic. In one room, cold, fever, pain and muscular pain are mainly prescribed as cold flushing, fever, and asthma.
갈근의 활성성분으로 이소플라보노이드에 대한 연구가 활발히 진행되고 있으며, 그 중 퓨에라린과 다이드진, 다이드제인 등이 해열작용, 진경작용, 혈당강하작용, 혈소판응집 억제작용, 알코올섭취 억제작용 등에 대한 연구결과가 보고되어 있다. Studies on isoflavonoids have been actively conducted as an active ingredient of P. grisea. Among them, fuerelin, daidzin, and daidzein have been known to have antipyretic action, antipyretic action, hypoglycemic action, platelet aggregation inhibitory action, Have been reported.
인삼(Ginseng Radix Alba)은 오갈피나무과(Araliaceae)의 속하며, 특이한 냄새가 있고, 맛은 처음에 약간 달다가 나중에 약간 쓴맛이 나타난다. Ginseng (Radix Alba) belongs to the family Araliaceae and has an unusual smell. The taste is slightly sweet at first and then bitter afterwards.
인삼의 유효성분은 주로 다마란(Dammarane)계 사포닌으로 프로토파낙사디올(Protopanaxadiol) 유도체인 진세노사이드(Ginsenoside) Ra1, Ra2, Rb1, Rb2, Rb3, Rc, Rd 등을 함유하고 있고, 프로토파낙사트리올(Protopanaxatriol) 유도체인 진세노사이드(Ginsenoside) Re, Rf, Rg1, Rg2, Rh1 등을 함유하고 있으며, 올레아난(Oleanane)계 사포닌으로 진세노사이드(Ginsenoside) Ro등을 함유하고 있다. The active ingredient of ginseng is mainly Dammarane saponin, which contains protopanaxadiol derivatives Ginsenoside Ra1, Ra2, Rb1, Rb2, Rb3, Rc, Rd, (Ginsenoside) Re, Rf, Rg1, Rg2, Rh1 and the like, which are Protopanaxatriol derivatives, and Oleanane saponin and Ginsenoside Ro.
인삼의 약리작용은 혈중 중성 지방의 생성을 억제하고, 혈전 생성을 방지하며, 혈소판 응고를 억제하여 혈액 순환을 촉진시키고, 대뇌 피질을 자극하여 말초 혈류를 증진하며, 위벽의 혈액 순환을 향상시킬 수 있다. 또한, 골수 세포의 단백질 합성 능력의 강화 및 적혈구 생성의 촉진을 통해 체력을 강화시키고, 신경의 흥분전도를 가속화시키며, 조건반사 능력을 강화하여 피로를 경감시키고, 소화액의 분비를 증진시켜 식욕을 강화하며, 위장의 연동 운동을 항진하여 소화 흡수를 촉진시키는 효과를 나타낸다. 또한, 지질 분해 작용이 있어 알코올 과음으로 인한 지방간의 예방과 개선효과를 나타내고, 강장작용과 함께 위장의 운동능력을 항진시키는 것으로 알려져 있다. The pharmacological action of ginseng inhibits blood triglyceride production, prevents thrombogenesis, promotes blood circulation by inhibiting platelet coagulation, stimulates the cerebral cortex to promote peripheral blood flow, and improves blood circulation in the gastric wall have. It also enhances the protein synthesis ability of bone marrow cells and promotes erythropoiesis, accelerates the excitement conduction of the nerves, enhances the condition reflection ability to alleviate fatigue, enhances the secretion of digestive juices, and strengthens appetite And stimulates the peristalsis of the stomach to promote digestion and absorption. In addition, it has a lipid-decomposing action, and it is known to exhibit prevention and improvement effects of fatty liver due to alcoholic liquor, and to enhance gastrointestinal motility along with tonic action.
인삼의 활성성분으로 각종 진세노사이드에 대한 연구가 활발히 진행되고 있는데, 면역증강작용, 중추신경에 대한 작용, 심혈관계에 대한 작용, 혈당강하작용, 지질대사에 대한 작용, 항암작용, 간세포보호작용, 학습능력개선작용, 피로회복 및 스트레스 저하작용, 발모촉진작용 등 다양한 연구결과가 보고되어 있다. Studies on various ginsenosides as an active ingredient of ginseng have been actively carried out. Immunostimulation, action on the central nervous system, action on cardiovascular, hypoglycemic action, action on lipid metabolism, anti-cancer action, hepatocyte protective action , Learning ability improvement action, fatigue recovery and stress reduction action, and hair growth promoting action have been reported.
황금이나 천마의 활성성분을 추출하여 약제나 기능성 음료 등으로 활용하려는 시도가 있으나, 추출물 제조 과정에서 활성성분이 크게 증가하지 않고 오히려 감소하거나 활성성분이 균일하게 추출되지 못하는 문제점이 있었다. 또한 뇌혈관 질환 및 뇌신경질환을 예방하고 개선하기 위한 황금, 천마, 진피, 갈근 및 인삼 등의 약리 성분을 모두 함유하며 이들의 활성성분을 증가시킨 복합 분말의 필요성이 제기되고 있다. There is an attempt to extract active ingredients of gold or horse meat and use them as medicines or functional beverages. However, there is a problem in that the active ingredient is not greatly increased in the process of producing the extract, but rather is decreased or the active ingredient can not be uniformly extracted. In addition, there is a need for a composite powder containing all of pharmacological components such as gold, chymase, dermis, pupa, and ginseng for increasing and preventing cerebrovascular disease and brain nerve disease, and increasing their active ingredients.
본 발명은 황금 생약의 항산화 활성을 증가시키고 천마의 신경전달 작용을 높여 주는 복합 분말을 제공하는 것이다. The present invention provides a composite powder which increases antioxidative activity of golden herbal medicine and enhances neurotransmitter action of chimpanzee.
본 발명은 황금, 천마, 진피, 갈근 및 인삼 등의 약리 성분을 모두 함유하며 또한, 이들의 활성성분을 증가시킨 복합 분말을 제공하는 것이다. The present invention is to provide a composite powder containing all of pharmacological components such as gold, chymus, dermis, pupa, ginseng and the like and also having an increased active ingredient.
본 발명은 고지혈증, 동맥경화, 뇌혈관 질환, 기억력 개선, 뇌신경질환의 예방 및 개선에 효능이 있는 복합 분말을 제공하는 것이다. The present invention provides a composite powder that is effective for preventing and improving hyperlipidemia, arteriosclerosis, cerebrovascular disease, memory improvement, and brain cirrhosis.
본 발명은 미생물 배양 농축분말과 과일효소 농축액을 혼합한 미생물-효소 복합 발효액을 황금(Scutellaria Radix)에 넣어주는 단계 ; The present invention relates to a method for fermenting a fermented microorganism, comprising the steps of: putting a microorganism-enzyme complex fermentation broth obtained by mixing a concentrated microorganism powder and a fruit enzyme concentrate into a scutellaria radix;
상기 황금을 발효시키는 단계 ; 및 Fermenting the gold; And
발효된 삼채를 소정 시간 숙성시킨 후 건조하는 단계를 포함하되, 상기 미생물이 락토바실러스 애씨도필러스(Lactobacillus acidophilus MG501), 스트렙토코커스 써모필러스(Streptococcus thermophilus) 및 사카로마이세스 세레비시아(Saccharomyces cerevisiae)중 어느 하나 이상인 발효 황금 제조방법을 제공한다. And aging the fermented trihydrate for a predetermined period of time and drying the microorganism, wherein the microorganism is selected from the group consisting of Lactobacillus acidophilus MG501, Streptococcus thermophilus, and Saccharomyces cerevisiae cerevisiae. < / RTI >
본 발명은 상기에서 제조된 발효황금, 천마, 진피, 갈근 및 인삼의 복합 추출액을 제조하는 단계 ; The present invention relates to a method for preparing a fermented golden, chestnut, dermis, pupa, and ginseng complex extract prepared as described above;
상기 복합추출액을 농축기에 넣고 감압 조건에서 가온 농축하는 복합 농축액 제조 단계 ; 및 A step of preparing a complex concentrate which is obtained by concentrating the complex extract in a concentrator and heating under reduced pressure; And
상기 복합 농축액에 정제수를 가한 다음 분무 건조시켜 복합추출 분말을 제조하는 단계를 포함하는 발효황금 천마 복합 추출 분말 제조방법에을 제공한다. Adding purified water to the complex concentrate, and spray drying the concentrate to prepare a combined extract powder.
본 발명을 통하여 미생물 및 천연효소 복합 발효액을 사용하여 황금 생약을 발효시킨 후, 발효황금에 천마, 진피, 갈근 및 인삼 등을 배합하여 추출 및 농축한 후 분무 건조과정을 거쳐 발효황금 천마복합 분말원료로 제조함으로써, 활성산소에 대한 항산화 활성을 증강시키고 고지혈증, 동맥경화, 뇌혈관 질환, 기억력 개선, 뇌신경질환의 예방 및 개선에 효능이 있다. The present invention relates to a method for fermenting a golden herbal medicine by using a microbial and natural enzyme complex fermentation broth, and then fermenting the fermentation product with a mixture of chimma, dermis, pupa, ginseng and the like, To enhance antioxidant activity against active oxygen and to prevent and improve hyperlipidemia, arteriosclerosis, cerebrovascular disease, memory improvement, and brain cirrhosis.
도 1은 본 발명의 일 실시예에 따라 유산균 및 천연효소 복합발효액을 사용하여 황금 생약을 발효숙성 및 건조과정을 거쳐 발효황금을 제조하는 과정을 나타낸 단계별 흐름도이다.
도 2는 본 발명의 다른 실시예에 따라 장내균 및 천연효소 복합발효액을 사용하여 황금 생약을 발효숙성 및 건조과정을 거쳐 발효황금을 제조하는 과정을 나타낸 단계별 흐름도이다.
도 3은 본 발명의 또 다른 실시예에 따라 효모균 및 천연효소 복합발효액을 사용하여 황금 생약을 발효숙성 및 건조과정을 거쳐 발효황금을 제조하는 과정을 나타낸 단계별 흐름도이다.
도 4는 본 발명의 실시예에 따라 발효황금, 천마, 진피, 갈근 및 인삼 생약을 혼합한 후 추출, 농축 및 분무과정을 거쳐 발효황금 천마복합 추출분말을 제조하는 과정을 나타낸 단계별 흐름도이다.
도 5a, 도 5b는 본 발명의 실시예에 따라 제조된 황금 및 발효황금의 HPLC 크로마토그램을 나타낸 비교한 도면이다.
도 6은 본 발명의 실시예에 따라 첨가된 천마의 HPLC 크로마토그램을 나타낸 그래프이다.
도 7은 본 발명의 실시예에 따라 첨가된 진피의 HPLC 크로마토그램을 나타낸 그래프이다.
도 8은 본 발명의 실시예에 따라 제조된 황금 분말과 발효황금 원료의 DPPH법에 의한 활성산소 라디칼 소거활성을 비교한 도면이다.
도 9는 본 발명의 실시예에 따라 제조된 황금 분말과 발효황금 원료의 키산틴법에 의한 슈퍼옥시드 라디칼 소거활성을 비교한 도면이다.
도 10은 본 발명의 실시예에 따라 제조된 황금 분말과 발효황금 원료의 그리스법에 의한 NO 라디칼 소거활성을 비교한 도면이다.
도 11a는 본 발명의 실시예에 따라 제조된 발효황금 천마복합 추출분말의 농도별 PC12 신경세포의 신경돌기 성장효과를 전자현미경으로 관찰한 도면이다.
도 11b는 본 발명의 실시예에 따라 제조된 발효황금 천마복합 추출분말의 농도별 PC12 신경세포의 신경돌기 성장길이를 비교한 도면이다. FIG. 1 is a flowchart showing a process for preparing fermented gold by fermentation aging and drying a golden herbal medicine using lactic acid bacteria and natural enzyme complex fermentation broth according to an embodiment of the present invention.
FIG. 2 is a flow chart showing a process of preparing fermented gold by fermentation aging and drying process of golden herbal medicine using enterobacteria and natural enzyme complex fermentation broth according to another embodiment of the present invention.
FIG. 3 is a flow chart showing a process of preparing fermented gold by fermentation aging and drying a golden herbal medicine using yeast and natural enzyme complex fermentation broth according to still another embodiment of the present invention.
FIG. 4 is a flow chart showing a process of preparing a fermented golden chromosome complex extract powder by mixing fermented gold, chymase, dermis, prawn, and ginseng herbal medicine according to an embodiment of the present invention, followed by extraction, concentration and spraying.
Figures 5a and 5b are comparative HPLC chromatograms of gold and fermented gold prepared according to an embodiment of the present invention.
FIG. 6 is a graph showing an HPLC chromatogram of a chimpanzee added according to an embodiment of the present invention.
7 is a graph showing an HPLC chromatogram of dermis added according to an embodiment of the present invention.
FIG. 8 is a graph comparing active oxygen radical scavenging activities of the gold powder and the fermentation golden raw material prepared according to the embodiment of the present invention by the DPPH method. FIG.
9 is a graph comparing the superoxide radical scavenging activity of the golden powder and the fermentation golden raw material prepared according to the embodiment of the present invention by the xanthine method.
10 is a graph comparing the NO radical scavenging activity of a golden powder and a fermentation golden raw material produced according to an embodiment of the present invention by a grease method.
FIG. 11A is an electron microscopic observation of the growth of neurite outgrowth of PC12 neurons according to the concentration of fermented golden chromosomal complex extract powder prepared according to an embodiment of the present invention. FIG.
FIG. 11B is a graph comparing the growth lengths of neurite outgrowths of PC12 neurons according to the concentration of fermented golden chromosomal complex extract powder prepared according to an embodiment of the present invention.
도 1 내지 도 3은 발효 황금을 제조하는 방법을 나타낸 것이다. 본 발명의 발효 황금 제조방법은 복합발효액을 황금에 침지시키는 단계, 발효 단계, 숙성 단계 및 건조 단계를 포함한다. Figures 1 to 3 illustrate a method for preparing fermentation gold. The fermentation gold manufacturing method of the present invention includes a step of immersing the complex fermentation broth in gold, a fermentation step, an aging step and a drying step.
먼저, 본 발명은 미생물 배양 농축분말과 과일효소 농축액을 혼합한 미생물-효소 복합 발효액을 제조하는 단계를 포함한다. First, the present invention includes a step of preparing a microbial-enzyme complex fermentation broth by mixing a microbial culture concentrated powder and a fruit enzyme concentrate.
도 1 내지 도 3을 참고하면, 미생물-효소 복합 발효액은 하기 과정을 거친다. 본 발명에서 사용되는 미생물은 유산균과 효모이다. 1 to 3, the microorganism-enzyme complex fermentation broth is subjected to the following procedure. The microorganisms used in the present invention are lactic acid bacteria and yeast.
상기 미생물 분말은 배지에 미생물 균주를 접종하여 계대 배양을 한 후, 이를 건조시켜 분말화한다. The microorganism powder is inoculated with a microorganism strain in a culture medium, followed by subculture, followed by drying and pulverizing.
또한, 천연효소는 미숙성 월하시에 백당을 혼합하고 이를 6개월 발효후 여과 농축을 하여 수득한다. In addition, the natural enzyme is obtained by mixing white sugar at an immature month and fermenting it for 6 months, followed by filtration and concentration.
미생물-효소 복합 발효액은 앞에서 제조한 미생물 분말과 효소 농축액을 혼합하여 제조한다. The microbial-enzyme complex fermentation broth is prepared by mixing the previously prepared microbial powder with an enzyme concentrate.
본 발명에서 사용가능한 미생물 균주는 락토바실러스 애씨도필러스(Lactobacillus acidophilus), 스트렙토코커스 써모필러스(Streptococcus thermophilus) 및 사카로마이세스 세레비시아(Saccharomyces cerevisiae)중 어느 하나 이상을 사용할 수 있다. The microorganism strain usable in the present invention may be any one or more of Lactobacillus acidophilus, Streptococcus thermophilus, and Saccharomyces cerevisiae.
본 발명에서의 발효는 미생물-효소 복합 발효액을 황금에 넣어 일정시간 동안 발효시킨다. 상기 황금은 황금 생약을 건조하고 절단한 후 이를 사용한다. In the present invention, the microorganism-enzyme complex fermentation broth is put into gold and fermented for a predetermined time. The gold is used to dry and cut gold medicinal herbs.
상기 발효는 1~3차에 걸쳐 다양한 방법으로 진행될 수 있다. The fermentation may be carried out in one to three different ways.
상기 미생물-효소 복합 발효액을 황금이 침지되도록 첨가한다. 황금이 침지된 상태에서 소정 시간, 바람직하게는 실온에서 하루 정도 방치시킬 수 있다. The microorganism-enzyme complex fermentation broth is added so that gold is immersed therein. The gold can be allowed to stand in the immersed state for a predetermined time, preferably at room temperature for a day.
상기 1차 발효 단계는 발효조에서 수일 동안 발효하는 단계이다. 예를 들면, 상기 1차 발효는 45~55℃를 유지하면서 5~10일, 바람직하게는 7일 동안 발효할 수 있다. The primary fermentation step is a fermentation step for several days in a fermentation tank. For example, the primary fermentation can be fermented for 5 to 10 days, preferably 7 days, while maintaining 45 to 55 ° C.
상기 2차 발효는 상기 미생물 - 효소 복합 발효액을 상기 황금에 분사하여 45~55℃를 유지하면서 5~10일, 바람직하게는 7일 동안 발효할 수 있다. 3차 발효는 2차 발효와 같은 조건으로 발효를 추가로 진행할 수 있다. The secondary fermentation may be performed by spraying the microorganism-enzyme complex fermentation broth onto the gold and fermenting the fermented product for 5 to 10 days, preferably 7 days, while maintaining the temperature at 45 to 55 ° C. The third fermentation can be further fermented under the same conditions as the second fermentation.
상기 숙성 및 건조 단계는 다양한 방법으로 수행될 수 있지만, 바람직하게는 40~50℃의 온도에서 대류열 순환방식과 40~60%의 습도를 유지하면서 대류열을 이용한 습식가열을 통하여 3일 동안 숙성시킨 후, 30~40℃에서 통풍 건조시킬 수 있다. The aging and drying steps may be carried out in various ways, but preferably at a temperature of 40 to 50 ° C, while maintaining a humidity of 40 to 60% and a convection heat cycle, Followed by air drying at 30 to 40 ° C.
본 발명의 발효황금 제조방법은 발효, 숙성 및 건조의 전 과정을 동일 발효용기 내에서 연속적으로 이루어지므로, 공정진행이 간편하고 제품의 균일성을 얻을 수 있는 장점이 있다. 본 발명의 방법은 제품의 발효상태를 보다 균일하게 하고 상품성을 높이기 위하여 3단계의 발효와 숙성 및 건조 단계를 포함한다. The fermentation gold manufacturing method of the present invention is advantageous in that the entire process of fermentation, aging, and drying is continuously performed in the same fermentation vessel, so that the process is simple and the uniformity of the product can be obtained. The method of the present invention includes three stages of fermentation, aging and drying in order to make the fermentation state of the product more uniform and increase the commerciality.
다른 양상에서, 본 발명은 복합추출액 제조, 복합농축액 제조 단계를 거쳐 발효 황금 천마 복합 분말 제조 방법을 제공한다. In another aspect, the present invention provides a method for preparing a fermented golden chromosomal complex powder through the steps of preparing a complex extract and preparing a complex concentrate.
상기 복합 추출액은 상기 발효황금, 천마, 진피, 갈근 및 인삼으로부터 복합 추출액을 제조한다. The combined extract produces a combined extract from the fermented golden, chunmei, dermis, pupa, and ginseng.
상기 추출액을 제조하는 방법은 공지된 다양한 방법, 용매 추출법, 가열 가압 추출법등을 사용할 수 있다. 예를 들면, 상기 발효황금, 천마, 진피, 갈근 및 인삼을 각 추출 용기에 넣고 알코올 용액이나 물을 가하고 소정 온도에서 가온 추출하여 추출액을 제조할 수 있다. As the method for producing the above extract, various known methods, solvent extraction method, heated pressure extraction method and the like can be used. For example, the fermented gold, chymus, dermis, pupa, and ginseng may be placed in each extraction container, alcohol solution or water may be added, and the extract may be heated and extracted at a predetermined temperature.
본 발명에서는 3 단계에 걸쳐 추출액을 제조한다. 상기 방법에 의해 유효 성분의 손실을 최소화하여 추출할 수 있다. 또한, 본 발명의 용매 추출법은 3차에 걸친 용매 추출과정에서 천마의 유효 성분인 가스트로딘을 가수분해하여 파라히드록시벤질알코올로 변화시키고 잔류 가스트로딘의 추출효율을 높이게되며, 가스트로딘 및 파라히드록시벤질알코올은 스코플라민, 아포모르핀 및 시클로헥시미드 등에 의한 기억력 장애를 회복시키는 것으로 보고되어 있다. In the present invention, an extract is prepared in three steps. By this method, it is possible to extract by minimizing the loss of the active ingredient. Further, in the solvent extraction method of the present invention, gastrodine, which is an active ingredient of horse chestnut, is hydrolyzed to a parahydroxybenzyl alcohol in a third solvent extraction process to increase extraction efficiency of residual gastrodine, Roxy benzyl alcohol has been reported to restore memory impairment by scopolamine, apomorphine, and cycloheximide.
좀 더 구체적으로, 상기 복합 추출액 제조 단계는 발효황금, 천마,진피, 갈근 및 인삼을 각 추출용기에 넣고 50% 알코올 용액을 가하여 80~90℃에서 가온 추출하고, 추출액을 여과기를 통해 여과한 1차 추출액과, 30% 알코올 용액을 가하여 80~90℃에서 가온 추출하고 추출액을 여과기를 통해 여과한 2차 추출액과, 정제수를 가하여 80~90℃에서 가온 추출하고 추출액을 여과기를 통해 여과한 3차 추출액을 합하여 제조할 수 있다. More specifically, in the step of preparing the complex extract, fermented gold, chymus, dermis, pupa, and ginseng are placed in each extraction container, and the mixture is warmed at 80 to 90 ° C with 50% alcohol solution. The extract is filtered through a filter The tea extract and the 30% alcohol solution were added and the mixture was warmed at 80 to 90 ° C. The extract was filtered through a filter, and purified water was added thereto. The extract was warmed at 80 to 90 ° C and the extract was filtered through a filter And the extract can be combined.
상기 추출액 제조 단계에서는 각 성분의 함량을 적절히 조절할 수 있다. 예를 들면, 인삼 100중량부 대비, 황금 200~400중량부, 천마, 진피, 갈근 각각 150~300중량부를 사용할 수 있다. The content of each component can be appropriately controlled in the step of preparing the extract. For example, 200 to 400 parts by weight of gold, 150 to 300 parts by weight of ginseng, dermis, and ginseng can be used as 100 parts by weight of ginseng.
상기 농축액 제조 단계는 상기 복합추출액을 농축기에 넣고 감압 조건에서 가온 농축할 수 있다. 예를 들면, 상기 추출액을 합한 후 농축기에 넣고 60℃에서 500~700mmHg 감압조건으로 농축시켜 60~100brix 범위의 농축액을 수득할 수 있다. In the concentrate preparation step, the combined extract may be put into a concentrator and concentrated under heating at reduced pressure. For example, after adding the above extracts, they are added to a concentrator and concentrated under reduced pressure of 500 to 700 mmHg at 60 DEG C to obtain a concentrate in the range of 60 to 100 brix.
상기 복합 추출 분말은 상기 복합 농축액에 정제수를 가한 다음 분무 건조시켜 제조할 수 있다. The combined extract powder can be prepared by adding purified water to the combined concentrate and then spray drying.
본 발명의 실시예들의 목적은 이상에서 언급한 목적으로 제한되지 않으며, 언급되지 않은 또 다른 목적들은 아래의 기재로부터 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다. The objects of the embodiments of the present invention are not limited to the above-mentioned objects, and other objects not mentioned can be clearly understood by those skilled in the art from the following description .
[실시예 1][Example 1]
먼저 황금 생약을 건조하고 절단한 후 황금절편 1kg을 취하고, 여기에 유산균의 일종인 락토바실러스 애시도필러스(Lactobacillus acidophilus) 균주배양 농축분말(균수 1x10 cfu/g) 5.0g과 천연효소농축액 5.0g을 정제수 5L에 혼합한 유산균·효소 복합 발효액 2L를 건조 황금에 침지하였다. 이어서, 황금을 실온에서 24시간동안 방치시킨 다음, 발효용기에 넣어 45~55℃를 유지하면서 7일 동안 1차 발효시키고, 다시 유산균·효소 복합 발효액 1.5L를 분사하여 동일한 조건에서 2차 발효시킨 후, 다시 동일한 방법으로 3차 발효를 진행하였다. 3차 발효 후 40~50℃에서 40~60%의 습도를 유지하면서 대류열을 이용한 습식가열과 대류열 순환방식을 3일 동안 숙성시킨 후, 30~40℃에서 통풍 건조시켜 발효황금을 얻었다. First, the golden herbal medicine was dried and cut, and then 1 kg of the golden slice was taken. 5.0 g of Lactobacillus acidophilus strain cultured as a kind of lactic acid bacteria (1 x 10 < 10 > cfu / g) Was mixed with 5 L of purified water, and 2 L of lactic acid bacteria / enzyme complex fermentation broth was immersed in dried gold. Then, the gold was allowed to stand at room temperature for 24 hours, and then fermented for 7 days while kept at 45 to 55 ° C in a fermentation vessel. Then, 1.5 L of the fermented lactic acid bacteria / Then, the third fermentation was carried out in the same manner. After the third fermentation, wet heat and convective heat circulation method using convection heat was maintained for 40 ~ 60% at 40 ~ 50 ℃ for 3 days, and then dried at 30 ~ 40 ℃ to obtain fermentation gold.
[실시예 2][Example 2]
미생물로 장내균의 일종인 스트랩토코커스 써모필러스(Streptococcus thermophilus)균주배양 농축분말(균수 1x10 cfu/g)을 사용한 것을 제외하고 실시예 1과 동일하게 수행하였다. The same procedure as in Example 1 was carried out except that Streptococcus thermophilus strain cultured as a microorganism, which is a kind of enterobacteria, was used (1 x 10 < 6 > cfu / g).
[실시예 3][Example 3]
미생물로 효모균의 일종인 사카로마이세스 세레비시아(Saccharomyces cerevisiae)균주배양 농축분말(균수 1x10 cfu/g)을 사용한 것을 제외하고 실시예 1과 동일하게 수행하였다. The same procedure as in Example 1 was carried out except that Saccharomyces cerevisiae strain cultured as a microorganism, a kind of yeast, was cultured in a concentration of 1 x 10 < 6 > cfu / g.
[실시예 4][Example 4]
실시예 1의 발효황금 3kg에 천마 2kg, 진피 2kg, 갈근 2kg 및 인삼 1kg을 각각 추출용기에 넣고 50%알코올 용액 100L를 가하여 80~90℃에서 8시간동안 가온 추출하고 추출액을 여과기를 통해 여과한 후 1차 추출액으로 하고, 다시 30% 알코올 용액 100L를 가하여 80~90℃에서 8시간동안 가온 추출하고 추출액을 여과기를 통해 여과한 후 2차 추출액으로 하며, 또 다시 정제수 100L를 가하여 80~90℃에서 10시간동안 가온 추출하고 추출액을 여과기를 통해 여과한 후 3차 추출액으로 하였다. To 3 kg of fermentation gold of Example 1, 2 kg of ginseng, 2 kg of dandruff, 2 kg of puffed ginger and 1 kg of ginseng were put into an extraction container, 100 L of a 50% alcohol solution was added, and the mixture was heated at 80 to 90 ° C for 8 hours. The extract was filtered through a filter After adding 100 L of a 30% alcohol solution, the mixture was warmed at 80 to 90 ° C for 8 hours. The extract was filtered through a filter and used as a secondary extract. 100 L of purified water was further added thereto, For 10 hours, and the extract was filtered through a filter to obtain a tertiary extract.
1차, 2차, 3차 추출액을 합하여 농축기에 넣고 60℃에서 500~700mmHg 감압조건으로 농축시켜 65brix 농축액을 만들었다. 상기 농축액에 정제수를 가하여 185~195℃에서 분무건조를 시킴으로써 발효황금 천마복합 추출분말을 만들었다. The primary, secondary and tertiary extracts were combined and concentrated in a concentrator at 60 ° C under reduced pressure of 500 to 700 mmHg to produce a 65brix concentrate. Purified water was added to the concentrate, followed by spray drying at 185 to 195 ° C to prepare a fermented golden chromatin composite extract powder.
도 5a, 도 5b는 본 발명의 실시예에 따라 제조된 황금 및 발효황금의 HPLC 크로마토그램을 나타낸 비교한 도면으로써 상술한 바와 같은 과정에 따라 제조된 발효황금을 분석한 결과에 대해 설명한다. FIGS. 5A and 5B are graphs showing HPLC chromatograms of gold and fermented gold prepared according to an embodiment of the present invention. FIG. 5A and FIG. 5B illustrate results of analysis of fermented gold prepared according to the procedure described above.
발효황금 추출분말의 고속 액체 크로마토그래피에 의한 유효성분을 확인 및 정량하면, 발효황금 농축액 50mg에 메탄올을 가해 용해시키고, 전량을 50mL로 한 후 시료액으로 사용하고, 별도로 황금 농축액 50mg을 각각 메탄올 50mL에 녹인 후 비교액으로 사용하였다. When 50 mg of the fermented golden concentrate was dissolved and dissolved in methanol, the total volume was adjusted to 50 mL, and then 50 mg of the golden concentrate was separately added to 50 mL of methanol And then used as a reference solution.
칼럼은 μ-Bondapak C18(Waters, ID 3.9mm × 30cm, U.S.A), 이동 용매로는 아세토니트릴 : 0.5% 인산용액(27 : 73 v/v)을 사용하였으며, 검액은 20㎕를 주입하였고, 검출기는 UV detector로서 파장은 328nm, 유속은 1.0 ㎖/min로 한 후, 얻어진 크로마토그램의 면적을 측정하여 검량선법에 의해 함량을 계산하였다. Acetonitrile: 0.5% phosphoric acid solution (27: 73 v / v) was used as a mobile solvent, and 20 μl of the sample solution was injected. Was a UV detector with a wavelength of 328 nm and a flow rate of 1.0 ml / min. The area of the obtained chromatogram was measured and the content was calculated by the calibration curve method.
그 결과, 도 5a 및 도 5b에 도시한 바와 같이 황금 추출물 중 바이칼린과 바이칼레인의 유지시간은 각각 3.50분과 5.30분으로 나타났다. 도 5a는 황금 농축액의 피크를 나타내고, 도 5b는 발효황금 농축액의 피크를 나타내며, 도 5a와 5b의 BA는 바이칼린 피크를 나타내고, BE는 바이칼레인 피크를 나타낸다. 바이칼린의 함량을 비교해보면 황금이 8.54%인데 비하여 발효황금에서는 18.67%로 나타나 2배 이상 증가하였고, 바이칼레인의 함량은 황금에서 1.04%이었으나 발효황금에서는 4.28%로 나타나 약 4배정도 유효성분이 증가하였음을 알 수 있다. 이는 발효황금이 황금에 비하여 유효성분의 수용성이 증가됨으로써, 추출효율이 높아졌음을 나타낸다. As a result, as shown in FIGS. 5A and 5B, the retention times of the baicalin and baicalein among the gold extracts were 3.50 minutes and 5.30 minutes, respectively. Fig. 5A shows the peak of the golden concentrate, Fig. 5B shows the peak of the fermented golden concentrate, BA in Figs. 5A and 5B shows the bicalin peak, and BE shows the bicalan peak. The content of Baikalin was 8.54% in gold compared to that of fermented gold, and increased to 18.67% in fermentation gold. The content of baicalein was 1.04% in gold and 4.28% in fermentation gold. . This indicates that the extraction efficiency is improved by increasing the water solubility of the active ingredient compared to the fermented gold.
도 6은 본 발명의 실시예에 따라 첨가된 천마의 HPLC 크로마토그램을 나타낸 도면으로써, 발효황금 천마복합 추출분말을 상술한 바와 같은 과정에 따라 첨가된 천마성분을 분석한 결과에 대해 설명한다. FIG. 6 is a graph showing an HPLC chromatogram of a chimpanzee added in accordance with an embodiment of the present invention. The result of analyzing the chimney ingredient added to the fermented golden chromosome complex extracted powder according to the procedure described above will be described.
고속 액체 크로마토그래피에 의한 유효성분을 확인 및 정량하면, 발효황금 천마복합 추출분말 농축액 50mg에 정제수를 가해 가온용해시키고, 전량을 50mL로 한 후 시료액으로 사용하였고, 가스트로딘(GA), 파라히드록시 벤질알코올(HBA) 및 파라히드록시벤즈알데히드(HBL)의 표준품을 비교표준액으로 하였다. When the active ingredient was identified and quantitated by high performance liquid chromatography, purified water was added to 50 mg of the fermented golden Gunma complex extracted powder concentrate to dissolve by heating, and the total volume was adjusted to 50 mL, and then used as a sample solution. Gastrodin (GA) A standard product of hydroxybenzyl alcohol (HBA) and parahydroxybenzaldehyde (HBL) was used as a standard solution for comparison.
칼럼은 Phenomenex Gemini NX C18 (4.6 × 150 mm, 3 μm pore size), 이동 용매로는 물/아세트니트릴(A/B,v/v)을 0 min-3% B, 5 min-3% B, 12 min-10% B, 20 min-10% B, 27 min-25% B, 32 min-25% B, 38 min-40% B, 42 min-60% B, 45 min-60% B, 48 min-20% B, 50 min-3 %비율로 변화시켰으며, 검액은 15㎕를 주입하였고, 검출기는 UV detector로서 파장은 220nm, 유속은 0.6 ㎖/min로 한 후, 얻어진 크로마토그램의 면적을 측정하여 검량선법에 의해 함량을 계산하였다. The columns were Phenomenex Gemini NX C18 (4.6 × 150 mm, 3 μm pore size) and water / acetonitrile (A / B, v / v) as mobile solvents at 0 min -3% B, 5 min -3% 30 min-60% B, 45 min-60% B, 48 min-25% B, 38 min-40% min, 20% B, and 50 min-3%, and 15 μl of the sample solution was injected. The detector was a UV detector with a wavelength of 220 nm and a flow rate of 0.6 ml / min. And the content was calculated by the calibration curve method.
그 결과, 도 6에 도시한 바와 같이 발효황금 천마복합 추출분말 중 가스트로딘(GA), 파라히드록시벤질알코올(HBA) 및 파라히드록시벤즈알데히드(HBL)의 유지시간은 각각 7.86분과 13.79, 24.56분으로 나타났다. 6, the retention times of gastrodine (GA), parahydroxybenzyl alcohol (HBA) and parahydroxybenzaldehyde (HBL) were 7.86 minutes and 13.79, 24.56 minutes Respectively.
가스트로딘(GA)의 함량은 33.5μ이였으며, 파라히드록시벤질알코올(HBA)은 193.0μ로써 가스트로딘에 비하여 5.8배 높게 나타났고, 파라히드록시벤즈알데히드(HBL)의 함량은 4.5μ로 낮게 나타났다. The content of gastrolidine (GA) was 33.5μ, and the parahydroxybenzyl alcohol (HBA) was 193.0μ, which was 5.8 times higher than that of gastroline and the content of parahydroxybenzaldehyde (HBL) was as low as 4.5μ .
이 결과는 발효황금 천마복합 추출분말의 3차에 걸친 용매 추출과정에서 가스트로딘이 가수분해되어 파라히드록시벤질알코올로 변화됨을 알 수 있다. 파라히드록시벤질알코올은 스코플라민, 아포모르핀 및 시클로헥시미드 등에 의한 기억력 장애를 회복시키는 것으로 보고되어 있다. These results indicate that gastrodine is hydrolyzed and converted into parahydroxybenzyl alcohol during the third extraction of the fermented Ganoderma lucidum extract powder. Parahydroxybenzyl alcohol has been reported to restore memory impairment by scopulmine, apomorphine, and cycloheximide.
도 7은 본 발명의 실시예에 따라 첨가된 진피의 HPLC 크로마토그램을 나타낸 도면으로써, 발효황금 천마복합 추출분말을 상술한 바와 같은 과정에 따라 첨가된 진피성분을 분석한 결과에 대해 설명한다. FIG. 7 is a graph showing an HPLC chromatogram of a dermis added according to an embodiment of the present invention. The result of analyzing the dermis component added to the fermented golden chromosome complex extracted powder according to the procedure described above will be described.
고속 액체 크로마토그래피에 의한 성분 확인 및 분석은 발효황금 천마복합 추출분말 농축액 50mg에 메탄올을 가해 용해시키고, 전량을 50mL로 한 후 시료액으로 사용하였고, 헤스페리딘(Hesperidin)의 표준품을 비교표준액으로 하였다. Component identification and analysis by high performance liquid chromatography were carried out by dissolving methanol in 50 mg of the fermented golden chromosomal complex extract powder and dissolving the whole amount to 50 mL, and used as a sample solution, and a standard solution of hesperidin (Hesperidin) was used as a standard solution.
칼럼은 μ-Bondapak C18(Waters, ID 3.9mm × 30cm, U.S.A), 이동 용매로는 메탄올 : 물(40 : 60 v/v)을 사용하였으며, 검액은 20㎕를 주입하였고, 검출기는 UV detector로서 파장은 280nm, 유속은 1.0 ㎖/min로 한 후, 얻어진 크로마토그램의 면적을 측정하여 검량선법에 의해 함량을 계산하였다. The column used was μ-Bondapak C18 (Waters, ID 3.9 mm × 30 cm, USA), methanol: water (40:60 v / v) was used as the mobile solvent and 20 μl of the sample solution was injected. The wavelength was 280 nm and the flow rate was 1.0 ml / min. The area of the obtained chromatogram was measured and the content was calculated by the calibration curve method.
그 결과 진피 중 헤스페리딘의 유지시간은 2.91분으로 나타났으며, As a result, the retention time of hesperidin in the dermis was 2.91 minutes,
발효황금 천마복합 추출분말 중 헤스페리딘의 함량은 16.5%의 높은 비율을 나타내었다.The content of hesperidin in fermented golden chromosomal complex extract powder was 16.5%.
도 8은 본 발명의 실시예에 따라 제조된 황금 분말과 발효황금 분말의 DPPH법에 의한 활성산소 라디칼 소거활성을 비교한 도면으로써, 황금 농축액 및 발효황금 농축액의 항산화 효과에 대한 비교 측정을 해보면, 주성분 및 히드로겔의 항산화 소거 활성 측정은 DPPH(1,1-diphenyl -2-picryl hydrazil) 방법을 응용하여 측정하였다. FIG. 8 is a graph comparing the activity of the radical scavenging activity of DPPH by the gold powder and the fermentation gold powder prepared according to the example of the present invention. As a comparative measure of the antioxidative effect of the golden concentrate and the fermented golden concentrate, The DPPH (1,1-diphenyl-2-picryl hydrazil) method was applied to measure the antioxidative scavenging activity of the main component and the hydrogel.
그 실험 방법은 0.2mM DPPH 메탄올 용액 0.5mL 에 시료를 여러 농도로 희석한 용액 1mL를 가하고, 교반기로 10초간 진탕한 후 20℃에서 30분간 방치한 다음 517nm에서 흡광도를 측정하였다. 여기에서, 비교 표준물질로는 비타민 C를 사용하였다. The test was carried out by adding 1 mL of a diluted sample solution to 0.5 mL of a 0.2 mM DPPH methanol solution, shaking it for 10 seconds with an agitator, incubating at 20 ° C for 30 minutes, and measuring the absorbance at 517 nm. Here, vitamin C was used as a reference material for comparison.
활성의 크기는 DPPH(66.7uM)의 농도가 50% 감소되는데 필요한 시료의 농도(Free Radical Scavenging Activity, FSC50, ug/mL)와 DPPH에 대한 전자 공여능(Electron Donating Ability, EDA%)으로 아래의 수학식 1과 같이 나타내었다. The size of the activity was determined by the following equation for the concentration of the sample (Free Radical Scavenging Activity, FSC50, ug / mL) and the electron donating ability (EDA%) for DPPH in which the concentration of DPPH (66.7uM) 1 < / RTI >
여기서, Sample ABS는 시료를 가한 시험액의 흡광도를 나타내고, Control ABS는 시료 대신 메탄올을 가한 시험액의 흡광도를 나타낸다. Here, Sample ABS represents the absorbance of the test liquid to which the sample is added, and Control ABS represents the absorbance of the test liquid to which methanol is added instead of the sample.
그 결과 황금이 44.3%이었으나, 발효황금에서는 89.8%로서 2배 이상 높은 활성산소 라디칼 소거활성을 나타내었다. As a result, gold was 44.3%, but in fermentation gold, it was 89.8%, showing more than 2 times of active oxygen radical scavenging activity.
도 9는 본 발명의 실시예에 따라 제조된 황금 분말과 발효황금 분말의 키산틴법에 의한 슈퍼옥시드 라디칼 소거활성을 비교한 도면으로써, 황금 농축액 및 발효황금 농축액의 항산화 효과에 대한 비교 측정을 해보면, 주성분 및 히드로겔의 항산화 소거 활성 측정은 키산틴법에 의한 슈퍼옥시드 라디칼 소거 활성 측정법을 응용하여 측정하였다. FIG. 9 is a graph comparing the superoxide radical scavenging activity of the gold powder and the fermentation gold powder prepared according to the embodiment of the present invention by the xanthine method. The comparative measurement of the antioxidative effect of the golden concentrate and the fermented golden concentrate , And the antioxidative scavenging activities of the main components and the hydrogels were measured by the supernatant radical scavenging activity measurement method using the xylanthin method.
그 실험 방법은 NBT(Nitro Blue Tetrazoliun) 및 키산틴(1.6mM)의 완충용액(20mM, pH 7.8)에 키산틴 옥시다제(0.05U/mL)100μL 적가하면서 37℃에서 30분간 배양한 후 분광광도계로 517nm에서 흡광도를 사용하여 NBT 환원능력을 측정하였다. The experiment was carried out at 37 ° C for 30 minutes while adding 100 μL of xanthine oxidase (0.05 U / mL) to a buffer solution (20 mM, pH 7.8) of NBT (Nitro Blue Tetrazoliun) The absorbance at 517 nm was used to determine the NBT reduction capacity.
그 결과 황금이 15.4% 이었으나, 발효황금에서는 58.5%로서 3배 이상 높은 슈퍼옥시드 라디칼 소거활성을 나타내었다. As a result, gold was 15.4%, but in fermentation gold, it was 58.5%, showing more than three times the superoxide radical scavenging activity.
도 10은 본 발명의 실시예에 따라 제조된 황금 분말과 발효황금 분말의 그리스법에 의한 NO(Nitrite oxide)라디칼 소거활성을 비교한 도면으로써, 황금 및 발효황금의 항산화 소거 활성 측정은 그리스법에 의한 NO(Nitrite oxide)라디칼 소거활성 측정법을 응용하여 측정하였다. FIG. 10 is a graph comparing nitric oxide (NO) radical scavenging activity of a gold powder and a fermentation gold powder produced according to an embodiment of the present invention by a grease method. The antioxidative scavenging activity of gold and fermented gold was measured by a grease method (Nitrite oxide) radical scavenging activity measurement method.
그 실험 방법은 소디움 니트로프루시드 용액(10mM)에 시료를 가하고, 그리스시액(0.2% 나프칠에칠렌디아민염산, 2% 설파닐아미드,5% 인산용액)에 교반기로 10초간 진탕한 후 20℃에서 2시간 방치한 다음 570nm에서 흡광도를 측정하였다. 여기에서, 비교 표준물질로는 비타민 C를 사용하였다. The test was carried out by adding a sample to a sodium nitroprusside solution (10 mM), shaking it in a grease solution (0.2% naphthenic ethylenediamine hydrochloride, 2% sulfanilamide, 5% phosphoric acid solution) for 10 seconds with a stirrer, After standing for 2 hours, the absorbance was measured at 570 nm. Here, vitamin C was used as a reference material for comparison.
그 결과 황금이 10.0%이었으나 발효황금에서는 34.0%로서 3배 이상 높은 NO라디칼 소거활성을 나타냈다. As a result, it was 10.0% in gold, but 34.0% in fermented gold showed NO radical scavenging activity more than 3 times.
도 11a 및 도 11b는 본 발명의 실시예에 따라 제조된 발효황금 천마복합 추출분말의 농도별 PC12 신경세포의 신경돌기 성장효과를 전자현미경으로 관찰한 도면으로써, 신경성장인자(neuronal growth factor, NGF)와 발효황금 천마복합 추출분말을 복합처리한 후, PC12신경세포의 신경돌기 길이 변화를 측정한 것이다. FIGS. 11A and 11B are electron micrographs of the neurite outgrowth of PC12 neurons according to the concentration of fermented golden chromosomal complex extract powder prepared according to the embodiment of the present invention. ) And fermented golden chromosomal complex extract powder, and then measured the change in the length of neurite of PC12 neurons.
그 실험 방법은 5ng/mL의 저농도 NGF와 황금발효 천마복합 추출분말의 농도를 각각 10, 50, 100, 200, 500㎍/mL로 혼합하여 처리하고, RPMI 1640배지를 사용하여 5일간 배양한 후 전자현미경을 통하여 PC12세포의 신경돌기 성장형태를 관찰하였고, 마이크로메터를 사용하여 신경돌기의 길이변화를 측정하였다. The experiment was carried out by mixing 5 ng / mL of low concentration NGF and 10 mg / mL of gold fermented Chunmei combined extract powder at 10, 50, 100, 200 and 500 ㎍ / mL, and culturing for 5 days using RPMI 1640 medium The morphology of PC12 cells was observed by electron microscope and the length of neurite was measured using a micrometer.
실험결과 NGF5ng/mL를 단독으로 처리한 신경돌기의 길이가 2.53㎛인 반면 NGF5ng/mL에 발효황금 천마복합 추출분말 50㎍/mL를 복합한 것은 124.4㎛㎛로써 신경돌기의 길이가 NGF 단독 처리군에 비하여 50배 정도 성장하였고, 발효황금 천마복합 추출분말 100㎍/mL를 복합한 것은 98.8㎛로써 40배정도 성장함으로써 월등하게 높은 성적을 나타내었다. Experimental results showed that the length of the neurites treated with 5 ng / mL of NGF alone was 2.53 μm, while the combination of 50 μg / mL of the fermented golden-chromosome complex extract powder with
한편, 200㎍/mL 및 500㎍/mL를 복합한 것은 각각 37.2㎛, 27.2㎛로써 고농도에서는 신경돌기의 성장 길이가 현저하게 감소하였다. On the other hand, the combined length of 200 ㎍ / mL and 500 ㎍ / mL was 37.2 ㎛ and 27.2 ㎛, respectively, and the growth length of neurite was remarkably decreased at high concentration.
상술한 바와 같이 본원 발명의 실시예에 따른 미생물 및 천연효소 복합액으로 발효숙성시킨 발효황금과 발효황금 천마 복합 추출 분말은 발효황금의 유효성분인 바이칼린과 바이칼렌이 증가하였으며, 또한, 천마의 유효성분인 가스트로딘의 함량도 5.8배 정도 증가하였다. 또한, 발효황금에서는 황금에 비해 높은 활성산소 라디칼 소거 능력을 보여주고 있다. As described above, the fermented golden and fermented golden ginseng extract powders fermented and aged with the microbial and natural enzyme complexes according to the embodiments of the present invention showed an increase in the active ingredients of fermented ginseng, bicalin and vicalan, The content of gastrodine, which is an active ingredient, also increased by 5.8 times. In fermentation gold, it shows higher ability of radical scavenging than gold.
본 발명의 발효황금과 발효황금 천마 복합 추출 분말은 고지혈증, 동맥경화, 뇌혈관 질환, 기억력 개선, 뇌신경질환의 예방 및 개선에 효능을 제공할 수 있다. The fermented gold and fermented golden ginseng extract powder of the present invention can provide an efficacy for the prevention and improvement of hyperlipidemia, atherosclerosis, cerebrovascular disease, memory improvement, and brain cirrhosis.
이상의 설명에서는 본 발명의 다양한 실시예들을 제시하여 설명하였으나 본 발명이 반드시 이에 한정되는 것은 아니며, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자라면 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 여러 가지 치환, 변형 및 변경이 가능함을 쉽게 알 수 있을 것이다. While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, It will be readily apparent that such substitutions, modifications, and alterations are possible.
Claims (4)
상기 황금을 발효시키는 단계 ; 및
발효된 삼채를 소정 시간 숙성시킨 후 건조하는 단계를 포함하되, 상기 미생물이 락토바실러스 애씨도필러스(Lactobacillus acidophilus), 스트렙토코커스 써모필러스(Streptococcus thermophilus) 및 사카로마이세스 세레비시아(Saccharomyces cerevisiae)중 어느 하나 이상인 것을 특징으로 하는 발효 황금 제조방법.Adding microbial-enzyme complex fermentation broth obtained by mixing concentrated microbial powder and fruit enzyme concentrate to gold (Scutellaria radix);
Fermenting the gold; And
And aging the fermented trihydrate for a predetermined period of time and drying the microorganism, wherein the microorganism is selected from the group consisting of Lactobacillus acidophilus, Streptococcus thermophilus, and Saccharomyces cerevisiae ). ≪ / RTI >
상기 복합추출액을 농축기에 넣고 감압 조건에서 가온 농축하는 복합 농축액 제조 단계 ; 및
상기 복합 농축액에 정제수를 가한 다음 분무 건조시켜 복합추출 분말을 제조하는 단계를 포함하는 발효황금 천마 복합 추출 분말 제조방법.Preparing a combined extract of fermented gold, chymus, dermis, pupa, and ginseng according to claim 1 or 2;
A step of preparing a complex concentrate which is obtained by concentrating the complex extract in a concentrator and heating under reduced pressure; And
Adding purified water to the complex concentrate, and spray drying the concentrate to prepare a combined extract powder.
[Claim 4] The method according to claim 3, wherein the step of preparing the complex extract comprises: fermenting gold, chymus, dermis, pupa, and ginseng in each extraction container, heating the mixture at 80 to 90 DEG C with a 50% alcohol solution, filtering the extract through a filter The first extract and the 30% alcohol solution were added and the mixture was warmed at 80 to 90 ° C. The extract was filtered through a filter, and purified water was added thereto. The extract was warmed at 80 to 90 ° C and the extract was filtered through a filter And extracting the tea extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150032888A KR101734022B1 (en) | 2015-03-10 | 2015-03-10 | Method of preparing combined extract powder of fermented scutellariae radix and gastrodiae rhizoma from compounding solution of micro-organism and natural enzyne |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150032888A KR101734022B1 (en) | 2015-03-10 | 2015-03-10 | Method of preparing combined extract powder of fermented scutellariae radix and gastrodiae rhizoma from compounding solution of micro-organism and natural enzyne |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20160109093A true KR20160109093A (en) | 2016-09-21 |
KR101734022B1 KR101734022B1 (en) | 2017-05-10 |
Family
ID=57080019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150032888A KR101734022B1 (en) | 2015-03-10 | 2015-03-10 | Method of preparing combined extract powder of fermented scutellariae radix and gastrodiae rhizoma from compounding solution of micro-organism and natural enzyne |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101734022B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110106224A (en) * | 2019-05-14 | 2019-08-09 | 昭通学院 | A kind of increased culture medium of promotion lactic acid granulose synthetic quantity and method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101249559B1 (en) * | 2011-10-18 | 2013-04-01 | 우석대학교 산학협력단 | Preparation method of concentrated powder included scutellaria radix and alnus japonica |
-
2015
- 2015-03-10 KR KR1020150032888A patent/KR101734022B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR101734022B1 (en) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2033528B1 (en) | Lingonberry extract, the preparing method and use thereof | |
EP3184628B1 (en) | Extract of panax ginseng including wild ginseng or ginseng, containing rare ginsenosides in high qunatity, plant stem cell derived from cambium of panax ginseng, or method for preparing extract thereof | |
JP2009013159A6 (en) | Cowberry extract and its production method and use | |
KR101339706B1 (en) | A compound for immune strengthen inclusion reducing the bitterness of red ginseng, the extract of immune, and the probiotics | |
CN110934803B (en) | Plant fermentation composition with whitening and spot-fading functions | |
KR20170061959A (en) | Preparation method of fermented ginseng and fermented black-red ginseng with active ginsenoside heightening rate absorption | |
KR101331171B1 (en) | Fermented-red gingseng or fermented-gingseng containing increased gensenoside rd and methods for preparation of the same | |
KR100824285B1 (en) | Processes for preparing a saccharified ginseng and ginseng extracts | |
KR20180110939A (en) | Composition for preventing hair loss and promoting hair growth comprising plant extract | |
KR101769184B1 (en) | Preparation for fermented ginseng or red ginseng extract containing increased ginsenoside Rd | |
KR20130003944A (en) | Methods for preparing fermented ginseng extracts | |
CN101433666B (en) | Anti-aging Chinese herbal medicinal composition, preparation method and use thereof | |
KR101201197B1 (en) | Making method of ginseng liquor using ginseng fermentation which were made by microorganism for ginseng fermentation | |
US20190000905A1 (en) | Gynostemma pentaphyllum fermented extracts comprising Saponins as an active functional food ingredient and preparation method thereof | |
KR20100079874A (en) | Preparation method of fermented ginseng or fermented red ginseng with active ginsenoside heightening absroption rate using lactic acid bacteria | |
KR101605057B1 (en) | Composition comprising fermented ginseng or red ginseng extract containing increased ginsenoside Rd for improving atopic dematitis | |
KR101253658B1 (en) | Manufacturing method of treated puffing and fermentation red ginseng concentrate | |
KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
KR20130059640A (en) | Composition for improving hair growth or preventing hair loss | |
KR101771788B1 (en) | Herbal composition comprising fermented scutellariae radix and gastrodiae rhizoma for the prevention and improvement of nerologic disease | |
KR101734022B1 (en) | Method of preparing combined extract powder of fermented scutellariae radix and gastrodiae rhizoma from compounding solution of micro-organism and natural enzyne | |
CN113893310A (en) | Mountain plant fermentation composition and preparation method and application thereof | |
CN110810693A (en) | A beverage composition containing Ampelopsis grossedentata and its preparation method | |
CN110537705A (en) | Probiotics fermented functional food for warming channels and dispelling cold and preparation method thereof | |
CN109628265A (en) | A kind of liver-protection health-care molecule wine and preparation method thereof containing general flavone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |